Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Wantagh, NY
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Wantagh, NY
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Cleveland, OH
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Lancaster, PA
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Rapid City, SD
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Memphis, TN
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Houston, TX
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
League City, TX
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
League City, TX
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
San Antonio, TX
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Little Rock, AR
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
San Antonio, TX
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated:  7/10/2014
Clinical Research Facility
mi
from
Houston, TX
Phase 3 Study of EBI-005 in Dry Eye Disease
A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease
Status: Enrolling
Updated: 7/10/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Demodex Blepharitis Treatment Study
Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial
Status: Enrolling
Updated:  7/15/2014
Ocular Surface Center
mi
from
Miami, FL
Demodex Blepharitis Treatment Study
Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial
Status: Enrolling
Updated: 7/15/2014
Ocular Surface Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome
A Phase 2, Single-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the CAE(SM) Model for the Treatment of Dry Eye Syndrome
Status: Enrolling
Updated:  7/21/2014
Clinical Research Facility
mi
from
Andover, MA
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome
A Phase 2, Single-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the CAE(SM) Model for the Treatment of Dry Eye Syndrome
Status: Enrolling
Updated: 7/21/2014
Clinical Research Facility
mi
from
Andover, MA
Click here to add this to my saved trials
Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects
Evaluation of Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects With Lipid Deficiency
Status: Enrolling
Updated:  7/22/2014
Alcon Call Center
mi
from
Fort Worth, TX
Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects
Evaluation of Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects With Lipid Deficiency
Status: Enrolling
Updated: 7/22/2014
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Birmingham, AL
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Phoenix, AZ
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Anaheim, CA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Bellflower, CA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Bellflower, CA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Glendale, CA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Huntington Beach, CA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Clearwater, FL
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Woodstock, GA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Woodstock, GA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Evansville, IN
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Newton, KA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Newton, KA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Whitehouse Station, NJ
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Whitehouse Station, NJ
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Huntersville, NC
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Huntersville, NC
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Winston Salem, NC
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Dayton, OH
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Corsicana, TX
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Corsicana, TX
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
San Antonio, TX
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Clinton, UT
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Clinton, UT
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Charlottesville, VA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Midlothian, VA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Midlothian, VA
Click here to add this to my saved trials
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
mi
from
Spokane, WA
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Selenium in Mild Thyroid Eye Disease in North America
Selenium - ITEDS: A North American Study
Status: Enrolling
Updated:  8/2/2014
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Selenium in Mild Thyroid Eye Disease in North America
Selenium - ITEDS: A North American Study
Status: Enrolling
Updated: 8/2/2014
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Selenium in Mild Thyroid Eye Disease in North America
Selenium - ITEDS: A North American Study
Status: Enrolling
Updated:  8/2/2014
Edward S. Harkness Eye Institute, Columbia University Medical Center, New York-Presbyterian Hospital
mi
from
New York, NY
Selenium in Mild Thyroid Eye Disease in North America
Selenium - ITEDS: A North American Study
Status: Enrolling
Updated: 8/2/2014
Edward S. Harkness Eye Institute, Columbia University Medical Center, New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Selenium in Mild Thyroid Eye Disease in North America
Selenium - ITEDS: A North American Study
Status: Enrolling
Updated:  8/2/2014
Ohio State University
mi
from
Columbus, OH
Selenium in Mild Thyroid Eye Disease in North America
Selenium - ITEDS: A North American Study
Status: Enrolling
Updated: 8/2/2014
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Status: Enrolling
Updated:  8/5/2014
Thomas Jefferson University
mi
from
Philadelphia, PA
Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Status: Enrolling
Updated: 8/5/2014
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Beta-carotene Absorption and Bioconversion to Vitamin A From Biofortified Cassava Gari
Beta-carotene Absorption and Bioconversion to Vitamin A in a Biofortified Cassava Gari Meal and a White Cassava Gari Meal With Added Red Palm Oil
Status: Enrolling
Updated:  8/5/2014
USDA, ARS, Western Human Nutrition Research Center
mi
from
Davis, CA
Beta-carotene Absorption and Bioconversion to Vitamin A From Biofortified Cassava Gari
Beta-carotene Absorption and Bioconversion to Vitamin A in a Biofortified Cassava Gari Meal and a White Cassava Gari Meal With Added Red Palm Oil
Status: Enrolling
Updated: 8/5/2014
USDA, ARS, Western Human Nutrition Research Center
mi
from
Davis, CA
Click here to add this to my saved trials
Nepafenac Once Daily for Macular Edema - Study 2
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery
Status: Enrolling
Updated:  8/8/2014
Alcon Call Center
mi
from
Fort Worth, TX
Nepafenac Once Daily for Macular Edema - Study 2
Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery
Status: Enrolling
Updated: 8/8/2014
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Birmingham, AL
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Goodyear, AZ
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Jonesboro, AR
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Little Rock, AR
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Encinitas, CA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Encinitas, CA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Fresno, CA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Huntington Beach, CA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
Irvine, CA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated:  8/14/2014
Clinical Research Facility
mi
from
La Jolla, CA
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)
Status: Enrolling
Updated: 8/14/2014
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials